SRT3

218.75

-2.86%↓

ORNBV.FI

68.9

+0.58%↑

PHMA

95.6

-1.49%↓

DRW3

90.6

-0.44%↓

SRT3

218.75

-2.86%↓

ORNBV.FI

68.9

+0.58%↑

PHMA

95.6

-1.49%↓

DRW3

90.6

-0.44%↓

SRT3

218.75

-2.86%↓

ORNBV.FI

68.9

+0.58%↑

PHMA

95.6

-1.49%↓

DRW3

90.6

-0.44%↓

SRT3

218.75

-2.86%↓

ORNBV.FI

68.9

+0.58%↑

PHMA

95.6

-1.49%↓

DRW3

90.6

-0.44%↓

SRT3

218.75

-2.86%↓

ORNBV.FI

68.9

+0.58%↑

PHMA

95.6

-1.49%↓

DRW3

90.6

-0.44%↓

Home・Stock List・Sanofi SA
Search

Sanofi SA

Open

SectorHealthcare

72.915 -0.95

Buy

Price update 8 May 2026, 13:07 UTC

BuySell

Overview

Share price change

24h

Current

Min

72.775

Max

74.4

Key metrics

By Trading Economics

Income

-394M

1.6B

Sales

-12B

11B

P/E

Sector Avg

20.158

49.8

EPS

1.34

Profit margin

14.354

Employees

74,846

EBITDA

1.5B

2.7B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+25.23% upside

Dividends

By Dow Jones

Next Earnings

30 Jul 2026

Market Stats

By TradingEconomics

Market Cap

-5.1B

94B

Previous open

73.87

Previous close

72.915

News Sentiment

By Acuity

43%

57%

141 / 347 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

91.3 / 96.1 Support & Resistance

Sanofi SA Chart

Past performance is not a reliable indicator of future results.

Related News

29 Apr 2026, 09:03 UTC

Earnings

Spain's Santander Profit Climbs Amid Global Portfolio Reshuffle -- Update

DJ

Read

29 Apr 2026, 05:27 UTC

Earnings

Santander Books Jump in Profit on Top-Line Growth, Lower Costs

DJ

Read

23 Apr 2026, 06:12 UTC

Earnings

Sanofi Posts Higher Sales Amid Leadership Transition

DJ

Read

7 May 2026, 06:47 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Sanofi Needs Acquisitions to Overcome Pipeline Disappointments -- Market Talk

DJ

Read

1 May 2026, 06:14 UTC

Acquisitions, Mergers, Takeovers

Santander UK to Also Pay GBP213M Based on TSB's Tangible NAV

DJ

Read

1 May 2026, 06:13 UTC

Acquisitions, Mergers, Takeovers

Santander UK Also Financed Deal From Funding by Parent, Banco Santander

DJ

Read

1 May 2026, 06:12 UTC

Acquisitions, Mergers, Takeovers

Santander UK Financed Deal From Existing Cash Resources

DJ

Read

1 May 2026, 06:08 UTC

Acquisitions, Mergers, Takeovers

Santander UK Announced Key Terms of Deal July 2025

DJ

Read

1 May 2026, 06:03 UTC

Acquisitions, Mergers, Takeovers

Santander UK Buys TSB Banking for GBP2.65B

DJ

Read

1 May 2026, 06:02 UTC

Acquisitions, Mergers, Takeovers

Santander UK Buys TSB Banking Group

DJ

Read

29 Apr 2026, 12:01 UTC

Earnings

Regeneron Earnings Beat Expectations. Upcoming Cancer Data Matter More for the Stock. -- Barrons.com

DJ

Read

29 Apr 2026, 06:27 UTC

Market Talk
Earnings

Santander's Above-Forecast Earnings Should Be Well-Received -- Market Talk

DJ

Read

29 Apr 2026, 04:55 UTC

Earnings

Analysts Saw Santander 1Q Loan Loss Provisions EUR3.12B

DJ

Read

29 Apr 2026, 04:55 UTC

Earnings

Santander 1Q Loan Loss Provisions EUR3.225B

DJ

Read

29 Apr 2026, 04:54 UTC

Earnings

Analysts Saw Santander 1Q Operating Expenses EUR6.57B

DJ

Read

29 Apr 2026, 04:54 UTC

Earnings

Santander 1Q Operating Expenses EUR6.48B

DJ

Read

29 Apr 2026, 04:52 UTC

Earnings

Santander Backs 2028 View

DJ

Read

29 Apr 2026, 04:52 UTC

Earnings

Santander Backs 2026 View

DJ

Read

29 Apr 2026, 04:52 UTC

Earnings

Santander 1Q Underlying RoTE 15.2%

DJ

Read

29 Apr 2026, 04:51 UTC

Earnings

Santander End-1Q CET1 Ratio 14.4%

DJ

Read

29 Apr 2026, 04:51 UTC

Earnings

Analysts Saw Santander 1Q Net Interest Income EUR10.86B

DJ

Read

29 Apr 2026, 04:51 UTC

Earnings

Santander 1Q Net Interest Income EUR11.02B

DJ

Read

29 Apr 2026, 04:50 UTC

Earnings

Analysts Saw Santander 1Q Underlying Net Pft EUR3.47B

DJ

Read

29 Apr 2026, 04:50 UTC

Earnings

Santander 1Q Underlying Pft EUR3.56B

DJ

Read

29 Apr 2026, 04:49 UTC

Earnings

Santander 1Q Net Pft EUR5.455B

DJ

Read

29 Apr 2026, 04:49 UTC

Earnings

Analysts Saw Santander 1Q Rev EUR15.00B

DJ

Read

29 Apr 2026, 04:49 UTC

Earnings

Santander 1Q Rev EUR15.14B

DJ

Read

27 Apr 2026, 09:32 UTC

Market Talk
Earnings

Sanofi's Dupixent Sales Growth Set to Moderate -- Market Talk

DJ

Read

27 Apr 2026, 09:19 UTC

Market Talk

Sanofi's New CEO Needs to Be Clear on Strategy -- Market Talk

DJ

Read

23 Apr 2026, 05:34 UTC

Earnings

Sanofi: 2026 Expectations Are at Constant Exchange Rates

DJ

Read

Peer Comparison

Price change

Sanofi SA Forecast

Price Target

By TipRanks

25.23% upside

12 Months Forecast

Average 93.471 EUR  25.23%

High 106.742 EUR

Low 79.807 EUR

Based on 10 Wall Street analysts offering 12 month price targets forSanofi SA - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

10 ratings

4

Buy

6

Hold

0

Sell

Based on 10 analysts giving stock ratings to Sanofi SA - Dist in the past 3 months.

Technical Score

By Trading Central

91.3 / 96.1Support & Resistance

Short Term

Very Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Intermediate Term

Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Long Term

Bullish Evidence

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

141 / 347 Healthcare

News Sentiment

Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Other stocks from the sector

SRT3

Sartorius AG

218.75

↓-2.86%

ORNBV.FI

Orion Oyj (Class B)

68.9

↑ +0.58%

PHMA

Pharma Mar SA

95.6

↓-1.49%

DRW3

Draegerwerk AG & Co KGaA- PREF

90.6

↓-0.44%
help-icon Live chat